REVIEW ARTICLE Upregulation of the a-secretase ADAM10 – risk or reason for hope? Kristina Endres and Falk Fahrenholz Department of Psychiatry and Psychotherapy, Clinical Research Group, Johannes Gutenberg-University, Mainz, Germany Identification of ADAM10 as a functional a-secretase A disintegrin and metalloproteinase 10 (ADAM10) originally came into focus in genetical and biochemical research as a peptide sequence purified from bovine brain myelin membrane preparations [1], and was referred to as MADM (i.e. mammalian disintegrin-me- talloprotease). Accidentally, this metalloproteinase was identified via an artifact resulting from in vitro studies: it has been described as a proteinase for the cytosolic myelin basic protein [2], which is a rather unphysiolog- ical substrate for the type I transmembrane enzyme ADAM10. Further studies revealed that ADAM10 is expressed in a wide variety of tissues either in Bos taurus [3] and, more interestingly, in distinct areas of the human brain [4,5] and peripheral structures [6,7]. Striking similarity concerning the inhibitory profile of ADAM10 [8] with the putative a-secretase [9] sug- gested a more physiological role for its enzymatic activity: overexpression of the ADAM10 cDNA in HEK293 cells first identified its function as an amyloid precursor protein (APP) cleaving a-secretase [8], which subsequently was verified in vivo. Alzheimer’s disease (AD) model mice, which were crossbred with ADAM10 transgenic mice, revealed a strongly attenu- ated plaque pathology and an enhanced production of the a-secretase derived soluble cleavage product APPs-a [10]. Furthermore, these mice had an increased learning and memory potential [10], which might correlate with the observed enhanced cholinergic and Keywords alpha-secretase; amyloid precursor protein; Alzheimer’s disease; domain structure; neuroprotection; shedding; synaptogenesis; TACE Correspondence K. Endres and F. Fahrenholz, Department of Psychiatry and Psychotherapy, Clinical Research Group, Johannes Gutenberg- University, 55131 Mainz, Germany Fax: + 49 6131 176690 Tel: + 49 6131 172133 E-mail: endres_k@psychiatrie.klinik. uni-mainz.de; fahrenho@uni-mainz.de (Received 4 November 2009, revised 10 December 2009, accepted 6 January 2010) doi:10.1111/j.1742-4658.2010.07566.x A decade ago, a disintegrin and metalloproteinase 10 (ADAM10) was iden- tified as an a-secretase and as a key proteinase in the processing of the amy- loid precursor protein. Accordingly, the important role that it plays in Alzheimer’s disease was manifested. Animal models with an overexpression of ADAM10 revealed a beneficial profile of the metalloproteinase with respect to learning and memory, plaque load and synaptogenesis. Therefore, ADAM10 presents a worthwhile target with respect to the treatment of a neurodegenerative disease such as Morbus Alzheimer. Initially, ADAM10 was suggested to be an enzyme, shaping the extracellular matrix by cleavage of collagen type IV, or to be a tumour necrosis factor a convertase. In a rel- atively short time, a wide variety of additional substrates (with amyloid pre- cursor protein probably being the most prominent) has been identified and the search is still ongoing. Hence, any side effects concerning the therapeutic enhancement of ADAM10 a-secretase activity have to be considered. The present review summarizes our knowledge about the structure and function of ADAM10 and highlights the opportunities for enhancing the expression and ⁄ or activity of the a-secretase as a therapeutic target. Abbreviations 5-HT4, serotonin 5-hydroxytryptamine; AD, Alzheimer’s disease; ADAM, a disintegrin and metalloproteinase; APP, amyloid precursor protein; Ab, b-amyloid protein; GPCR, G protein-coupled receptor; GPI, glycosylphosphatidylinositol; PACAP, pituitary adenylate cyclase-activating peptide; PKC, protein kinase C; SH3, Src homology 3; TACE, tumour necrosis factor a cleaving enzyme. FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS 1585 glutamatergic synaptogenesis [11]. By contrast, mice with a dominant negative mutant of ADAM10 had lowered amounts of APPs-a, accompanied by an enhanced amount of plaques [10] and learning deficien- cies in the Morris water maze test [12]. In summary, what began with a fallacious observation ended up with the discovery of an enzyme that might have impli- cations for a therapeutic approach in AD [13–15]. Protein structure and gene organization of ADAM10 The enzyme ADAM10 belongs to the subgroup of metzincins within the zinc proteinases family. The typi- cal multidomain structure of ADAM10 as a type I integral transmembrane protein consists of a prodo- main, a catalytical domain with a conserved zinc bind- ing sequence, a cysteine-rich disintegrin-like domain, a transmembrane domain and a rather short cytoplasmic domain (Fig. 1). The nascent protein itself is not functional and is produced as a zymogene. After cleavage of the signal- ling sequence, ADAM10 enters the secretory pathway to be processed and thereby activated by the propro- tein convertases furin or PC7 [16]. This constitutive processing has been demonstrated for the prodomains of several ADAMs [17–19]. Regarding ADAM10, the prodomain was revealed to exhibit a dual function: the separately expressed prodomain was capable of inacti- vating endogenous ADAM10 in cell culture experi- ments but overexpressed ADAM10 without its prodomain was inactive [16]. By contrast, coexpression of the prodomain in trans rescued the activity of the deletion mutant of ADAM10 without the intramolecu- lar prodomain [16]. In addition, the recombinant mur- ine prodomain purified from Escherichia coli acts as a potent and selective competitive inhibitor in experi- ments performed in vitro [20]. This implicates that the prodomain of ADAM10 acts not only as a transient inhibitor, but also as an internal chaperone in the mat- uration of the enzyme. Accordingly, the viral delivery of furin into the brain of AD model mice increased a-secretase activity and reduced b-amyloid protein (Ab) production in infected brain regions [21], demon- strating the in vivo relevance of the removal of the prodomain of ADAM10. Recently, by reciprocal coim- munoprecipitation, tetraspanin 12 was identified as an interaction partner for ADAM10 that enhances a-sec- retase shedding of APP, probably by regulating matu- ration of the prodomain of ADAM10 [22]. The catalytical domain of ADAM10 contains a typical zinc-binding consensus motif (HEXGHXX GXXHD; Fig. 1) and the point mutation E384A, which compromises this motif, leads to a substantial decrease in APPs-a secretion in HEK cells and in mice [10,23]. Glycosylation sites in the catalytic and disinte- grin domain contain high-mannose as well as complex- type N-glycans, and a mutation at the N-glycosylation site N439 increased ADAM10s susceptibility to proteo- lytical degradation [24]. Although the removal of the disintegrin domain of ADAM10 did not grossly affect shedding of APP in cell culture experiments [23], cleavage of some sub- strate molecules is likely to be influenced by noncata- lytical domains. For example, epidermal growth factor 3 708 | PKLPPPKPLPGTLKRRRPPQPIQQPQRQRPR pat.7 pat.4 bipartite 1 2 4 5 210 | RKKR 383 | HEVGHNFGSPHD Fig. 1. Domain structure of human ADAM10. ADAM10 is com- posed of five different domains: the prodomain (1) has bifunctional properties as an intramolecular chaperone and as an inhibitor of the catalytic function in the zymogene. By detaching the prodomain via proprotein convertase cleavage (recognition motif shown), the cata- lytic domain with the conserved zinc binding motiv (2) becomes activated. A mutation of the glutamate residue at position 384 (highlighted) into an alanine leads to a dominant-negative mutant of the enzyme. The cystein-rich disintegrin domain (3) is followed by a transmembrane region (4). In the intracellular space, a short cyto- plasmic domain protrudes (5), which contains important sequence motives for protein localization (SH3 motifs highlighted) [28,29]. In addition, nuclear localization sequences have been assumed because the ADAM10 intracellular domain was found to translocate to the nucleus [41,79]: PSORTII analysis indicates two pattern 4, one pattern 7 and one bipartite nuclear localization sequence (underlined). Upregulation of ADAM10 K. Endres and F. Fahrenholz 1586 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS cleavage is at least partially impaired in ADAM10 ) ⁄ ) cells overexpressing a cytoplasmic domain deletion mutant of ADAM10 [25]. In accordance with this find- ing, the cytoplasmic domain of ADAM10 contains an IQ consensus binding site for calmodulin that afflicts maturation of the proteinase [25]. Additionally, ADAM10 has been shown to be activated by a calcium ionophore and the calmodulin inhibitor triflu- oroperazine [26,27]. The cytoplasmic domain of ADAM10 furthermore contains two proline-rich puta- tive Src homology 3 (SH3) binding domains, from which the juxtamembrane domain affects basolateral localization of ADAM10 in epithelial cells [28]. In neu- rones, the SH3 binding domains direct ADAM10 via binding to synapse-associated protein-97 to the post- synaptic membrane [29]. In 1997, the gene locus for ADAM10 was matched to chromosome 15 in humans (15q21.3-q23) and chro- mosome 9 in mice [30,31]. Subsequently, it took 8 years to achieve further gene structure analysis and potential identification of transcription factor binding sites [32]. We now know that the human, mouse and rat genes, which comprise  160 kb, include a highly homologous sequence within the first 500 bp upstream of either translation initiation site. Deletion analysis defined nucleotides )508 to )300 bp as the human core promoter. This promoter was also identified as a TATA-less promoter with functional binding sites for Sp1, USF and retinoic acid receptors [32,33]. The func- tional promoter of  2 kb displayed activity in various human cell lines, such as HEK293, HepG2 or SH-SY5Y, which reflects the ubiquitous basal expres- sion of the endogenous ADAM10. Single nucleotide polymorphism analyses of the pro- moter region of 104 AD patients versus control patients (n = 84) did not lead to significant statistical differences [32]. In addition, an independent recent study, genotyping 27 single nucleotide polymorphisms covering the entire gene for ADAM10 in a larger cohort of patients (n = 438 AD; n = 290 control), revealed no single-marker or haplotypic association with the disease [34]. This indicated that the gene for ADAM10 probably does not constitute a major risk with regard to AD. Nevertheless, a very recent study of 1439 DNAs from 436 multiplex AD families yielded significant evidence for an association of AD with the metalloproteinase with respect to two mutations: Q170H and R181G [35]. Both mutations are located close to the cysteine switch within the prodomain and the proprotein convertase recognition site (Fig. 1), which explains their strong impact on enzyme func- tionality: Chinese hamster ovary cells stably overex- pressing mutated ADAM10 showed strongly attenuated a-secretase activity [35]. Although both mutations are rare (segregation in seven AD families out of 1004) and are only partially penetrant, these results give support to the hypothesis that the human gene for ADAM10 plays a role in the aetiology of AD. ADAM10 and tumour necrosis factor a (TACE): the ill-matched couple Three members of the ADAM family have been shown to act as a-secretase [8,36,37]: ADAM9, ADAM10 and ADAM17 (TACE). Overexpression of ADAM9 has been reported to increase the basal and protein kinase C (PKC) dependent APPs-a release [36], although the purified enzyme failed to cleave a synthetic peptide at the major a-secretase cleavage-site [17]. Additionally, mice lacking ADAM9 revealed no differences in the production of the a-secretase cleavage product of APP [38]. The impact of ADAM9 promoter polymorphism on sporadic AD, which has been described recently [39], might therefore rely on a more indirect mecha- nism: ADAM9 has been shown to proteolytically pro- cess ADAM10 [40–42]. By contrast to ADAM9, ADAM10 was found to have constitutive and regu- lated a-secretase activity as well as many other proper- ties expected for the a-secretase [8,10]. Moreover, in situ hybridization analysis in human cortical neuro- nes provided evidence for the coexpression of APP with ADAM10, suggesting that this proteinase is most likely the physiologically relevant a-secretase [4]. Finally, experiments performed with ADAM17 (TACE)-deficient cells indicated a participation of TACE in the regulated, PKC-stimulated [37,43] and the constitutive a-secretase pathway [44,45]. To our knowledge, there are no published reports about TACE acting as an in vivo APP-sheddase in transgenic mice, although TACE-positive neurones are found to colocalize with amyloid plaques in AD brains support- ing its role as an a-secretase [46]. On the basis of these results, it can be concluded that ADAM10 and TACE are the major sheddases that balance the b-site amyloid precursor protein cleav- ing enzyme-driven generation of Ab peptides. This is consistent with the close structural relationship of both metalloproteinases: although TACE of human origin has  30% amino acid identity relative to bovine ADAM10, it only shows  15% identity with ADAM9 [47]. Additionally, only those two ADAMs lack the RX(6)DLPEFa(9)b(1) integrin binding motif, which is contained in the other members of the pro- teinase family [48]. Nevertheless, there are significant differences between ADAM10 and TACE that K. Endres and F. Fahrenholz Upregulation of ADAM10 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS 1587 probably allow a specific modulation of one of them for therapeutic approaches. TACE not only differs in the consensus sequence of its disintegrin domain from ADAM10 or by including a Crambin-like domain [47], but also in its regulation. Several studies have described the treatment of cellular cultures with a dis- tinct outcome for either TACE or ADAM10 activity: for example, incubation with phorbol 12-myristate 13- acetate increased the turnover of TACE in Jurkat cells [49] and diminished the amount of mature TACE in HEK293 as well as in SH-SY5Y cells [45]. Interest- ingly, these cell lines did not show altered amounts of ADAM10, suggesting a significant difference in the cel- lular stability of the mature enzyme forms after treat- ment with 4b-phorbol 12-myristate 13-acetate [45]. In addition, ADAM10 and TACE vary in their reaction to cellular differentiation by retinoic acid [50,51] and active site determinants of substrate recognition [52]. ADAM10: not particular about its substrates? For the enzyme ADAM10, more than 40 substrates have been identified that belong to three different classes of membrane bound proteins [53]. Most of them are type I transmembrane proteins such as APP [8], APP- like protein 2 [50] or the receptor for glycosylation end products [54,55]. Type II transmembrane proteins such as the apoptosis-inducing Fas ligand [56,57] or Bri2 [58] have also been reported to be shed by ADAM10. Addi- tionally, at least three glycosylphosphatidylinositol (GPI)-anchored proteins are candidate substrates for ADAM10: the metastasis-associated protein C4.4A was characterized by a proteome technique as a substrate of ADAM10 [59]. Furthermore, the GPI-anchored neuro- nal guidance molecule ephrin A5 is cleaved by ADAM10 upon binding to its receptor EphA3, leading to termination of the receptor–ligand interaction [60]. Third, from cell culture experiments, the prion protein PrP c was suggested to be processed by ADAM10 [40,61] and the abundance of the PrP cleavage product C1 was associated with mature ADAM10 within a small set of human cerebral cortex samples [62]. However, in vivo overexpression of ADAM10 in mice reduced all cellular prion protein species instead of generating enhanced amounts of cleavage products [63]. The substrates of ADAM10 show a wide range of cellular function ADAM10 cleaves proteins that affect cell migration (N-cadherin [64]; transmembrane chemokines [65]) and cell proliferation (CXCL16 [66–68]). It also sheds pro- teins with functions in either the immune system (low affinity immunoglobulin E receptor [69,70]; vascular endothelial cadherin [71]) or in cell signalling (Delta [72]; Notch [73]). Most effects, provoked by ADAM10 shedding activity, have been associated with the huge N-terminal ectodomains of the substrates of ADAM10 that are released into the intercellular fluid upon cleav- age. However, some effects have clearly been matched to the intracellular domains of the substrates: ectodo- main shedding by ADAM10 is followed by regulated intramembrane proteolysis. After cleavage of the Notch receptor by ADAM10, c-secretase releases a small intracellular part of Notch, which then translo- cates to the nucleus and acts as a transcription factor [74–76]. With regard to Bri2, the ADAM10-derived cleavage is followed by signal peptide peptidase-like protease activity, also resulting in the release of a small Bri2 fragment into the cell body [58]. In summary, ADAM10 has a repertoire of different protein substrates hampering the development of ther- apeutic strategies that target specifically APP by ADAM10. However, not all substrates described as being cleaved in the in vitro system have been con- firmed in vivo. Mutagenesis experiments have depicted at least three residues in the S1¢ pocket of ADAM10 that strongly influence substrate specificity and also limit the number of substrates [52]. Additional interac- tions of ADAM10 noncatalytical domains with the substrate or with adaptor molecules, as previously described for the recognition of ephrins [60], also appear to be important for targeting ADAM10 to a distinct substrate in the physiological context. Regulators of ADAM10 expression and catalytical activity Because of the above-mentioned involvement of ADAM10 in a wide range of cellular functions, it is obvious to consider its therapeutic potential in various diseases such as cancer or AD. ADAM10 has been shown to cleave tumour-associated substrates such as MICA [77] or C4.4A [59] and to be linked to progres- sion of certain cancer types such as prostate or breast cancer [78–80]. Furthermore, it plays a role in metasta- sis of human colon cancer cells [81]. Therefore, the inhibition of ADAM10 might be helpful in cancer treatment in certain contexts [82]. By contrast, ADAM10 overexpression or activation in the brain might be beneficial for the treatment of neurodegenera- tive diseases, in particular AD: this progressive disor- der of the brain goes ahead with the loss of synaptic junctions and neuronal cells. For ADAM10 overex- pressing mice, it has been demonstrated that cortical Upregulation of ADAM10 K. Endres and F. Fahrenholz 1588 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS synaptogenesis is enhanced [11], long-term potentiation deficiency in AD model mice is rescued [10] and learn- ing, as well as memory, is positively influenced by ADAM10 [83]. Studies with the dominant negative form of ADAM10 in a mouse model of AD revealed that the enzymatic activity of ADAM10 is required to counteract cognitive deficits [12]. In addition, axonal guidance is conveyed by the metalloproteinase, as has been shown for retinal and peripheral axons [84,85], and ADAM10 regulates axon withdrawal by ephrin cleavage [60,86]. It remains a matter of controversy as to whether there is a substantial decline of neuronal ADAM10 in ageing or in the pathological context: healthy, ageing human fibroblasts did not reveal lowered amounts of ADAM10 during senescence [87], although its specific cleavage product APPs-a was decreased. Another study demonstrated ADAM10 mRNA to be upregulat- ed in cases of presenile dementia but to be downregu- lated in the brain of AD patients [4]. A decrease for ADAM10 and APPs-a was confirmed in human plate- lets [88,89] as well as for APPs-a in the cerebrospinal fluid of AD patients. Additionally, a recent study revealed that colocalization of ADAM10 and one of its potential regulators (i.e. nardilysin) is reduced in AD compared to healthy aged brains [90]. With regard to these reports and to studies with ADAM10 overexpression in a mouse AD model [10], in principal, the enhancement of ADAM10 activity and ⁄ or amount in the patient’s brain appears to be valuable. How can this be achieved? Different approaches appear to be promising, such as interfering with the transcription ⁄ translation of ADAM10 or reg- ulating its enzymatic capacity by influencing the mem- brane physiology or via protein interactions (Fig. 2). A first point of intervention within the biosynthetic pathway of ADAM10 is provided by directly interfer- ing with the expression of the gene for ADAM10: the promoter region of the gene for ADAM10 has been characterized in detail [32] and in silico analyses have provided a multitude of transcription factor binding sites. One of the putative binding sites for retinoic acid receptors located at )302 and )203 bp has been dem- onstrated to be functional by electrophoretic mobility shift assay, promoter assays and APPs-a secretion in human neuronal cells [32,50]. In addition, acitretin, which is an accredited synthetic retinoid drug, lowered Ab peptide generation in AD model mice and enhanced APPs-a secretion [33]. Acitretin, which is already used in the long-term treatment of patients suf- fering from skin diseases withdraws all-trans retinoic acid from its cellular retinoic acid binding protein and makes it available for activating the corresponding nuclear receptors. In the case of ADAM10 regulation, cell culture studies with a variety of ligands for nuclear receptors narrowed the receptors involved down to a nonpermissive retinoic acid receptor–retinoid X receptor heterodimer [33]. Another approach is offered by targeting the nascent ADAM10 molecules during maturation within the cell. Enhancement of the expression of a proprotein conver- tase such as furin will increase ADAM10 maturation Fig. 2. ADAM10 bears several points of vantage for its regulation. For regulating the amount or catalytic activity of ADAM10, different approaches such as interfering with membrane composition or pro- teolytical processing of the proteinase itself are conceivable. In addition, protein interaction partners such as TIMPs, tetraspanins or reversion-inducing cysteine-rich protein with Kazal motifs (RECK) modify the enzymatic property of ADAM10. GPCR-mediated cellular signalling has been described for PACAP binding to PAC1 and tran- scription factor based induction of gene expression (e.g. via retinoid acid receptors) also contributes to ADAM10 activity within the cell. Electrophoretic mobility shift assay experiments and application of nuclear receptor ligands to the human neuroblastoma cell line SH-SY5Y have identified important functional binding sites for non- permissive retinoic acid receptor–retinoid X receptor heterodimers at posititons )302 and ⁄ or )203 bp [32,33]. These can be directly stimulated by addition of all-trans retinoic acid (atRA) or indirectly by acitretin, liberating all-trans retinoic acid from cellular retinoic acid binding protein. Pathways or molecules positively influencing ADAM10 activity are indicated by a ‘+’ symbol, those with an inhibitory effect by a ‘)’ symbol and those with an unknown outcome by a ‘?’ symbol. K. Endres and F. Fahrenholz Upregulation of ADAM10 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS 1589 and a-secretase activity [21]. A further cleavage of ADAM10 has been described in close proximity to and within its transmembrane domain [40–42]. This is a result of metalloproteinases ADAM9 and 15 acting on ADAM10 to release a soluble sADAM10 from the cell surface. sADAM10 was incapable of shedding cell- associated amyloid precursor protein [42], whereas it cleaved a synthetic peptide substrate [41,42] and endogenous prion protein in cell culture experiments [40]. Because it is still unclear whether soluble ADAM10 and the transmembrane variant cleave the same substrates and whether they have the same cata- lytic properties in vivo, this type of regulation has to be elucidated further. Acetylcholine esterase inhibitors, which are already used in the symptomatic treatment of AD, enhance the transport of ADAM10 to the cell surface and the non-amylodogenic cleavage of APP [91,92]. ADAM10 has also been shown to be regulated by the lipid composition of the plasma membrane. While cholesterol depletion enhanced its activity [93,94], targeting ADAM10 via an artificial GPI-anchor to cholesterol-rich domains inhibited its enzymatic func- tion [95]. In human cells, the amount and activity of ADAM10 was enhanced by statin application [93]. However, the outcomes of clinical trials with the chol- esterol lowering statins are not unambiguous: several studies have reported a protective effect of statins against AD [96,97], although this could not be con- firmed in others [98,99]. Nevertheless, in the prospec- tive, population-based Rotterdam study comprising  7000 participants, the use of statins was associated with a lower risk of AD [100], preserving the hope of a therapeutic value for statins in AD therapy. Further evidence for lipids acting as modulators of a-secretase activity is provided by a study demonstrating that type III secretory phospholipase A and arachidonic acid increased APPs-a production most likely by enhancing substrate availability at the cell surface [101]. Another approach to activate ADAM10 could rest on noncovalent protein interaction partners of ADAM10. The tissue inhibitors of metalloproteinases 1 and 3 have been shown to inhibit ADAM10 in vitro [102] and the reversion-inducing cysteine-rich protein with Kazal motifs also comprises a physiological ADAM10 inhibi- tor [103]. By contrast, for the N-arginine dibasic convertase (nardilysin), an activating property for ADAM10-mediated APP a-secretase cleavage and tumour necrosis factor a cleavage has been reported [104,105]. The same holds true for the tetraspanins: tetraspanin 12 increases maturation and activity of ADAM10 [22] and ADAM10 has been suggested as a component of the ‘tetraspanin web’ [106], which also scaffolds heterotrimeric G protein-coupled receptors (GPCRs) [107]. For the development of drugs interact- ing with those proteins and thereby modulating ADAM10 activity, further studies are necessary. An appropriate strategy for targeting ADAM10 is presented by directly stimulating the ADAM10 activity by ligands of GPCRs. For example, the GPCR ligands LPA and bombesin induced ADAM10-driven epider- mal growth factor receptor transactivation [108] and shedding of the thyrotropin receptor by ADAM10 was mediated by its ligand thyrotropin [109]. At least in cell culture, the a-secretase cleavage of APP is induc- ible by the neuropeptide pituitary adenylate cyclase- activating peptide (PACAP), which involves signalling via mitogen-activated protein kinase and phosphatidyl- inositol 3-kinase [110]. These results are of special interest because the neuropeptide PACAP offers the opportunity of locally activating the PAC1 receptor and a-secretase in the brain. This also holds true for the serotonin 5-hydroxytryptamine (5-HT4) receptor, which increases memory and learning: the 5-HT4(e) receptor isoform induced a-secretase activity by the cAMP-regulated guanine exchange factor Epac and the small GTPase Rac [111,112]. This recently led to synthesis and evaluation of novel 5-HT4-agonists; two of them increased APPs-a production in the cortex and hippocampus of mice and exhibited neuroprotec- tive properties [113]. Therefore, GPCR ligands offer an interesting oppor- tunity in regulating ADAM10, even if the signalling pathways have not yet been elucidated in every detail. Another signalling pathway regulating ADAM10 activ- ity is connected with the PKC: in various in vitro stud- ies, it has been demonstrated that PKC or certain isoforms of PKC stimulate the a-secretase [114–116] (for the role of PKC in AD, see [117]) and this has been confirmed in AD model mice (e.g. bryostatin 1) [118]. ADAM10 as target for AD therapy: lessons learned from transgenic mice In summary, several independent strategies for enhanc- ing the amount or the catalytic activity of ADAM10 have been performed or are conceivable. The crucial question remaining is whether there are side effects connected with enhanced ADAM10 activity in the brain or in peripheral structures. ADAM10 mono- transgenic mice with a permanent neuronal overexpres- sion of ADAM10 to various extent were inconspicuous in morphology, breeding and in daily handling [10]. This indicates that, by overexpression of ADAM10 in the brain, the homeostasis of the entire organism is Upregulation of ADAM10 K. Endres and F. Fahrenholz 1590 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS not grossly affected. A more detailed behavioural examination showed that ADAM10 moderately over- expressing mice performed similar to controls with respect to basal activity, exploration and anxiety. In the Morris water maze hidden platform task, however, ADAM10 mono-transgenic mice showed thigmotaxis with floating behaviour, indicating differences in moti- vation [83]. Therefore, with respect to learning and memory, mono-transgenic ADAM10 mice displayed no specific phenotype. By contrast, overexpression of ADAM10 in an AD mouse model with mutated human APP created bi-transgenic mice with a clear improvement of memory and alleviation of learning deficits [10]. A recent microarray study [119] revealed that there was only a moderate alteration of gene expression in moderately ADAM10 overexpressing adult mice. Genes coding for pro-inflammatory or pro-apoptotic proteins were not over-represented among differentially regulated genes and, indeed, a decrease of inflamma- tion markers was observed. ADAM10 participates also in the activation of Notch1 signalling by cleaving the extracellular portion of this receptor upon ligand bind- ing. Young ADAM10 transgenic mice at postnatal day 15 showed a 40% induction of expression of the gene for Hes5, whereas a 50% reduction in mice overex- pressing the dominant negative variant of the enzyme was reported [119]. Nevertheless, in adult mice, no significant effects with respect to the amount of Notch1 target gene Hes5 mRNA were obtained, sug- gesting an attenuation of the signalling cascade during ageing. Because ADAM10-based AD therapy will take place in elderly people, interference with this important developmental signalling pathway does not appear to hamper such an approach. Regarding prion diseases, upregulation of ADAM10 might also be beneficial: the reduction of all species of the prion protein in ADAM10 overexpressing mice was accompanied by a prolonged survival time of the mice after Scrapie infection [63]. In addition, Akt phosphorylation as a marker for survival signals in neuronal cells [120] was not affected in ADAM10 moderately overexpressing mice [121]. Furthermore, the thickness of the myelin sheath was not altered by ADAM10 overexpression, demonstrating that neuregu- lin-1 acting as a modulator of this developmental event is not a substrate of ADAM10 [121]. In mice charac- terized by high levels of overexpressed ADAM10, how- ever, phosphorylation of Akt was reduced to  50% compared to wild-type mice and tomacula-like struc- tures (i.e. local myelin thickenings) were observed [121]. In addition, mice with high ADAM10 overex- pression showed more seizures and stronger neuronal damage and inflammation than wild-type mice upon kainate treatment [122]. By contrast, in the presence of its substrate APP in doses exceeding the endogenous level, ADAM10 revealed a protective effect [122]. If we consider all of the results obtained concerning increased ADAM10 activity in vivo, it can be con- cluded that this approach might be a valuable alterna- tive to other strategies, such as the inhibition of b-or c-secretase or immunization, for the treatment of AD. However, a-secretase activation must be moderate and closely monitored. Acknowledgements The authors’ own work is supported by the Federal Ministry of Education and Research (BMBF) in the Framework of the National Genome Research Network (NGFN), Fo ¨ rderkennzeichen FKZ01GS08130. References 1 Chantry A, Gregson NA & Glynn P (1989) A novel metalloproteinase associated with brain myelin membranes. Isolation and characterization. J Biol Chem 264, 21603–21607. 2 Chantry A, Gregson N & Glynn P (1992) Degradation of myelin basic protein by a membrane-associated metalloprotease: neural distribution of the enzyme. Neurochem Res 17, 861–867. 3 Howard L, Lu X, Mitchell S, Griffiths S & Glynn P (1996) Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types. Biochem J 317, 45–50. 4 Marcinkiewicz M & Seidah NG (2000) Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J Neurochem 75, 2133–2143. 5 Karkkainen I, Rybnikova E, Pelto-Huikko M & Huovila AP (2000) Metalloprotease-disintegrin (ADAM) genes are widely and differentially expressed in the adult CNS. Mol Cell Neurosci 15, 547–560. 6 Dallas DJ, Genever PG, Patton AJ, Millichip MI, McKie N & Skerry TM (1999) Localization of ADAM10 and Notch receptors in bone. Bone 25 , 9–15. 7 McKie N, Edwards T, Dallas DJ, Houghton A, Stringer B, Graham R, Russell G & Croucher PI (1997) Expres- sion of members of a novel membrane linked metallo- proteinase family (ADAM) in human articular chondrocytes. Biochem Biophys Res Commun 230, 335–339. 8 Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C & Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of K. Endres and F. Fahrenholz Upregulation of ADAM10 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS 1591 Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 96, 3922– 3927. 9 Roberts SB, Ripellino JA, Ingalls KM, Robakis NK & Felsenstein KM (1994) Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase. J Biol Chem 269, 3111–3116. 10 Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M et al. (2004) A disintegrin-metalloproteinase pre- vents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113, 1456–1464. 11 Bell KF, Zheng L, Fahrenholz F & Cuello AC (2008) ADAM-10 over-expression increases cortical synapto- genesis. Neurobiol Aging 29, 554–565. 12 Schroeder A, Fahrenholz F & Schmitt U (2009) Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer’s disease. J Alzheimers Dis 16, 309– 314. 13 Hooper NM & Turner AJ (2002) The search for alpha- secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem 9, 1107–1119. 14 Fahrenholz F & Postina R (2006) Alpha-secretase acti- vation – an approach to Alzheimer’s disease therapy. Neurodegener Dis 3, 255–261. 15 Fahrenholz F (2007) Alpha-secretase as a therapeutic target. Curr. Alzheimer Res. 4, 412–417. 16 Anders A, Gilbert S, Garten W, Postina R & Fahrenholz F (2001) Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein converta- ses. FASEB J 15, 1837–1839. 17 Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, Blackburn RK, Weskamp G, Tempst P & Blobel CP (1999) Metallo- protease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 274, 3531–3540. 18 Lum L, Reid MS & Blobel CP (1998) Intracellular maturation of the mouse metalloprotease disintegrin MDC15. J Biol Chem 273, 26236–26247. 19 Loechel F, Gilpin BJ, Engvall E, Albrechtsen R & Wewer UM (1998) Human ADAM 12 (meltrin alpha) is an active metalloprotease. J Biol Chem 273, 16993–16997. 20 Moss ML, Bomar M, Liu Q, Sage H, Dempsey P, Lenhart PM, Gillispie PA, Stoeck A, Wildeboer D, Bartsch JW et al. (2007) The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem 282, 35712–35721. 21 Hwang EM, Kim SK, Sohn JH, Lee JY, Kim Y, Kim YS & Mook-Jung I (2006) Furin is an endogenous regulator of alpha-secretase associated APP processing. Biochem Biophys Res Commun 349, 654–659. 22 Xu D, Sharma C & Hemler ME (2009) Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J 23, 3674–3681. 23 Fahrenholz F, Gilbert S, Kojro E, Lammich S & Postina R (2000) Alpha-secretase activity of the disin- tegrin metalloprotease ADAM 10. Influences of domain structure. Ann N Y Acad Sci 920, 215–222. 24 Escrevente C, Morais VA, Keller S, Soares CM, Altevogt P & Costa J (2008) Functional role of N-gly- cosylation from ADAM10 in processing, localization and activity of the enzyme. Biochim Biophys Acta 1780, 905–913. 25 Horiuchi K, Le GS, Schulte M, Yamaguchi T, Reiss K, Murphy G, Toyama Y, Hartmann D, Saftig P & Blobel CP (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regu- lation by phorbol esters and calcium influx. Mol Biol Cell 18, 176–188. 26 Nagano O, Murakami D, Hartmann D, De SB, Saftig P, Iwatsubo T, Nakajima M, Shinohara M & Saya H (2004) Cell-matrix interaction via CD44 is indepen- dently regulated by different metalloproteinases acti- vated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165 , 893–902. 27 Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, Raines EW, Dunbar AJ & Dempsey PJ (2005) ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmer- curic acetate and extracellular calcium influx. J Biol Chem 280, 1826–1837. 28 Wild-Bode C, Fellerer K, Kugler J, Haass C & Capell A (2006) A basolateral sorting signal directs ADAM10 to adherens junctions and is required for its function in cell migration. J Biol Chem 281, 23824–23829. 29 Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, Borroni B, Cattabeni F, Sala C, Padovani A et al. (2007) Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and pro- motes its activity. J Neurosci 27 , 1682–1691. 30 Yamazaki K, Mizui Y, Sagane K & Tanaka I (1997) Assignment of a disintegrin and metalloproteinase domain 10 (Adam10) gene to mouse chromosome 9. Genomics 46, 528–529. 31 Yamazaki K, Mizui Y & Tanaka I (1997) Radiation hybrid mapping of human ADAM10 gene to chromo- some 15. Genomics 45, 457–459. 32 Prinzen C, Muller U, Endres K, Fahrenholz F & Posti- na R (2005) Genomic structure and functional charac- terization of the human ADAM10 promoter. FASEB J 19, 1522–1524. 33 Tippmann F, Hundt J, Schneider A, Endres K & Fahrenholz F (2009) Up-regulation of the alpha- secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23, 1643–1654. Upregulation of ADAM10 K. Endres and F. Fahrenholz 1592 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS 34 Laws SM, Eckart K, Friedrich P, Kurz A, Forstl H & Riemenschneider M (2009) Lack of evidence to sup- port the association of polymorphisms within the alpha- and beta-secretase genes (ADAM10 ⁄ BACE1) with Alzheimer’s disease. Neurobiol Aging doi:10.1016/ j.neurobiolaging.2009.02.023. 35 Kim M, Suh J, Romano D, Truong MH, Mullin K, Hooli B, Norton D, Tesco G, Elliott K, Wagner SL et al. (2009) Potential late-onset Alzheimer’s disease- associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet 18 , 3987– 3996. 36 Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, Fujisawa-Sehara A, Ohno S, Suzuki K & Ishiura S (1999) Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor pro- tein. Biochem J 343, 371–375. 37 Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP & Black RA (1998) Evidence that tumor necrosis fac- tor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid pro- tein precursor. J Biol Chem 273, 27765–27767. 38 Weskamp G, Cai H, Brodie TA, Higashyama S, Manova K, Ludwig T & Blobel CP (2002) Mice lack- ing the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during develop- ment or adult life. Mol Cell Biol 22 , 1537–1544. 39 Cong L & Jia J (2009) Promoter polymorphisms which regulate ADAM9 transcription are protective against sporadic Alzheimer’s disease. Neurobiol Aging doi:10.1016/j.neurobiolaging.2009.01.001. 40 Cisse MA, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B & Checler F (2005) The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem 280, 40624–40631. 41 Tousseyn T, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, Maes E, Snellinx A, Serneels L, Nyabi O et al. (2009) ADAM10, the rate-limiting pro- tease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J Biol Chem 284, 11738–11747. 42 Parkin E & Harris B (2009) A disintegrin and metallo- proteinase (ADAM)-mediated ectodomain shedding of ADAM10. J Neurochem 108, 1464–1479. 43 Merlos-Suarez A, Fernandez-Larrea J, Reddy P, Base- lga J & Arribas J (1998) Pro-tumor necrosis factor- alpha processing activity is tightly controlled by a com- ponent that does not affect notch processing. J Biol Chem 273, 24955–24962. 44 Slack BE, Ma LK & Seah CC (2001) Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha con- verting enzyme. Biochem J 357, 787–794. 45 Endres K, Anders A, Kojro E, Gilbert S, Fahrenholz F & Postina R (2003) Tumor necrosis factor-alpha converting enzyme is processed by proprotein-conver- tases to its mature form which is degraded upon phorbol ester stimulation. Eur J Biochem 270, 2386– 2393. 46 Skovronsky DM, Fath S, Lee VM & Milla ME (2001) Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. J Neurobiol 49, 40–46. 47 Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S et al. (1997) A metalloproteinase disinte- grin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729–733. 48 Eto K, Huet C, Tarui T, Kupriyanov S, Liu HZ, Puzon-McLaughlin W, Zhang XP, Sheppard D, Engv- all E & Takada Y (2002) Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions. J Biol Chem 277, 17804–17810. 49 Doedens JR & Black RA (2000) Stimulation-induced down-regulation of tumor necrosis factor-alpha con- verting enzyme. J Biol Chem 275, 14598–14607. 50 Endres K., Postina R, Schroeder A, Mueller U & Fahrenholz F (2005) Shedding of the amyloid precur- sor protein-like protein APLP2 by disintegrin-metallo- proteinases. FEBS J 272, 5808–5820. 51 Holback S, Adlerz L, Gatsinzi T, Jacobsen KT & Iverfeldt K (2008) PI3-K- and PKC-dependent up-reg- ulation of APP processing enzymes by retinoic acid. Biochem Biophys Res Commun 365, 298–303. 52 Caescu CI, Jeschke GR & Turk BE (2009) Active site determinants of substrate recognition by the metallo- proteinases TACE and ADAM10. Biochem J 424, 79–88. 53 Pruessmeyer J & Ludwig A (2009) The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol 20, 164–174. 54 Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P & Bianchi ME (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteo- lytic cleavage of the membrane-bound form by the shed- dase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716–3727. 55 Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A & Postina R (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metallo- proteinases. J Biol Chem 283, 35507–35516. K. Endres and F. Fahrenholz Upregulation of ADAM10 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS 1593 56 Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Luckerath K, Friedmann E, Novac N, Wels WS, Martoglio B, Hueber AO et al. (2007) The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ 14 , 1678–1687. 57 Schulte M, Reiss K, Lettau M, Maretzky T, Ludwig A, Hartmann D, De SB, Janssen O & Saftig P (2007) ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation- induced cell death. Cell Death Differ 14, 1040–1049. 58 Martin L, Fluhrer R, Reiss K, Kremmer E, Saftig P & Haass C (2008) Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a ⁄ SPPL2b. J Biol Chem 283, 1644–1652. 59 Esselens CW, Malapeira J, Colome N, Moss M, Canals F & Arribas J (2008) Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biol Chem 389, 1075–1084. 60 Janes PW, Saha N, Barton WA, Kolev MV, Wimmer- Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M & Nikolov DB (2005) Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123, 291–304. 61 Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De SB, Grassi J, Lopez-Perez E & Checler F (2001) The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem 276, 37743–37746. 62 Laffont-Proust I, Faucheux BA, Hassig R, Sazdovitch V, Simon S, Grassi J, Hauw JJ, Moya KL & Haik S (2005) The N-terminal cleavage of cellular prion pro- tein in the human brain. FEBS Lett 579, 6333–6337. 63 Endres K, Mitteregger G, Kojro E, Kretzschmar H & Fahrenholz F (2009) Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo. Neurobiol Dis 36, 233–241. 64 Kohutek ZA, diPierro CG, Redpath GT & Hussaini IM (2009) ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration. J Neurosci 29, 4605–4615. 65 Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von HP, Winter U, Paliga K, Reiss K, Saftig P et al. (2007) Regulated shedding of trans- membrane chemokines by the disintegrin and metallo- proteinase 10 facilitates detachment of adherent leukocytes. J Immunol 178, 8064–8072. 66 Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ & Raines EW (2004) A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 172, 3678–3685. 67 Schulte A, Schulz B, Andrzejewski MG, Hundhausen C, Mletzko S, Achilles J, Reiss K, Paliga K, Weber C, John SR et al. (2007) Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. Biochem Biophys Res Commun 358, 233–240. 68 Schramme A, bdel-Bakky MS, Kampfer-Kolb N, Pfe- ilschifter J & Gutwein P (2008) The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells. Biochem Biophys Res Commun 370, 311–316. 69 Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S, Broadway N, Hartmann D, Saftig P, Umland S et al. (2006) ADAM10 is a principal ‘sheddase’ of the low-affinity immunoglobulin E recep- tor CD23. Nat Immunol 7, 1293–1298. 70 Lemieux GA, Blumenkron F, Yeung N, Zhou P, Wil- liams J, Grammer AC, Petrovich R, Lipsky PE, Moss ML & Werb Z (2007) The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. J Biol Chem 282, 14836–14844. 71 Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P & Reiss K (2008) ADAM10 regu- lates endothelial permeability and T-Cell transmigra- tion by proteolysis of vascular endothelial cadherin. Circ Res 102 , 1192–1201. 72 Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP & Zolkiewska A (2007) Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 282, 436–444. 73 Tian L, Wu X, Chi C, Han M, Xu T & Zhuang Y (2008) ADAM10 is essential for proteolytic activation of Notch during thymocyte development. Int Immunol 20, 1181–1187. 74 Schroeter EH, Kisslinger JA & Kopan R (1998) Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393, 382–386. 75 De SB, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ et al. (1999) A presenilin-1-dependent gamma- secretase-like protease mediates release of Notch intra- cellular domain. Nature 398, 518–522. 76 Cagavi BE & Weinmaster G (2009) Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 29, 5679–5695. 77 Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG & Steinle A (2008) Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68, 6368–6376. 78 McCulloch DR, Akl P, Samaratunga H, Herington AC & Odorico DM (2004) Expression of the disinte- grin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the Upregulation of ADAM10 K. Endres and F. Fahrenholz 1594 FEBS Journal 277 (2010) 1585–1596 ª 2010 The Authors Journal compilation ª 2010 FEBS [...]... Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice Behav Brain Res 175, 27 8–2 84 Chen YY, Hehr CL, tkinson-Leadbeater K, Hocking JC & McFarlane S (2007) Targeting of retinal axons requires the metalloproteinase ADAM10 J Neurosci 27, 844 8–8 456 Jangouk P, Dehmel T, Meyer Zu HG, Ludwig A, Lehmann HC & Kieseier BC (2009) Involvement of ADAM10 in axonal... co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer’s disease and Down syndrome brains Age (Dordr) 31, 1 1–2 5 Upregulation of ADAM10 91 Yogev-Falach M, Amit T, Bar-Am O, Weinstock M & Youdim MB (2002) Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline FASEB J 16, 167 4–1 676 92... receptor by ADAM10 is regulated by thyrotropin J Mol Recognit 20, 39 2–4 04 110 Kojro E, Postina R, Buro C, Meiringer C, GehrigBurger K & Fahrenholz F (2006) The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein FASEB J 20, 51 2–5 14 111 Robert S, Maillet M, Morel E, Launay JM, Fischmeister R, Mercken L & Lezoualc’h F (2005) Regulation of the amyloid... Selkoe DJ (1994) Selective ectodomain phosphorylation and regulated cleavage of beta-amyloid precursor protein EMBO J 13, 53 4–5 42 116 Skovronsky DM, Moore DB, Milla ME, Doms RW & Lee VM (2000) Protein kinase C-dependent alphasecretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network J Biol Chem 275, 256 8–2 575 117 Alkon DL, Sun MK & Nelson TJ (2007)... Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer’s disease J Med Chem 52, 221 4–2 225 114 Gillespie SL, Golde TE & Younkin SG (1992) Secretory processing of the Alzheimer amyloid beta ⁄ A4 protein precursor is increased by protein phosphorylation Biochem Biophys Res Commun 187, 128 5–1 290 115... central role of CD81 in facilitating GPR56-Galpha q ⁄ 11 association Mol Biol Cell 15, 237 5–2 387 108 Yan Y, Shirakabe K & Werb Z (2002) The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors J Cell Biol 158, 22 1–2 26 109 Kaczur V, Puskas LG, Nagy ZU, Miled N, Rebai A, Juhasz F, Kupihar Z, Zvara A, Hackler L Jr & Farid NR (2007) Cleavage of the human... outgrowth and myelination of the peripheral nerve Glia 57, 176 5–1 774 Hattori M, Osterfield M & Flanagan JG (2000) Regulated cleavage of a contact-mediated axon repellent Science 289, 136 0–1 365 Kern A, Roempp B, Prager K, Walter J & Behl C (2006) Down-regulation of endogenous amyloid precursor protein processing due to cellular aging J Biol Chem 281, 240 5–2 413 Colciaghi F, Borroni B, Pastorino L, Marcello E,... triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE) J Biol Chem 278, 3882 9–3 8839 95 Harris B, Pereira I & Parkin E (2009) Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein Brain Res 1296, 20 3–2 15 96 Wolozin B, Kellman W, Ruosseau P, Celesia GG & Siegel G (2000) Decreased prevalence of Alzheimer disease... Lyketsos CG et al (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study Arch Neurol 62, 104 7–1 051 99 Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA & Breitner JC (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study Arch Gen Psychiatry 62, 21 7–2 24 100 Haag MD, Hofman A, Koudstaal PJ, Stricker... (2007) PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer’s disease Trends Pharmacol Sci 28, 5 1–6 0 118 Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van dA I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP et al (2004) Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice Proc Natl Acad Sci U S A 101, 1114 1–1 1146 119 Prinzen C, Trumbach D, Wurst W, . ARTICLE Upregulation of the a-secretase ADAM10 – risk or reason for hope? Kristina Endres and Falk Fahrenholz Department of Psychiatry and Psychotherapy,. lower risk of AD [100], preserving the hope of a therapeutic value for statins in AD therapy. Further evidence for lipids acting as modulators of a-secretase activity